<DOC>
	<DOCNO>NCT02800590</DOCNO>
	<brief_summary>This phase II , two-part , multiple-dose , dose-finding , single-blind study adult participant undergo elective colonoscopy screen diagnostic purpose . This study design test various ABP-700 infusion regimens rational selection one dosage regimen ( ) use future clinical development ABP-700 procedural sedation .</brief_summary>
	<brief_title>Study Investigate Safety Efficacy 3 Dosing Regimens ABP-700 Procedural Sedation Adult Participants Undergoing Colonoscopy</brief_title>
	<detailed_description>In Part 1 , three ABP-700 two-stage infusion regimen evaluate . A sample size 75 evaluable participant randomly assign dose regimen 1:1:1 ratio . Following completion Part 1 , Data Review Committee ( DRC ) review dose-response , efficacy , safety data provide recommendation whether continue study Part 2 number ABP-700 infusion regimen include Part 2 . The Sponsor ( MDCO ) make final decision proceed Part 2 ( whether conduct Part 2 number dose regimen study continue Part 2 ) base recommendation DRC .</detailed_description>
	<criteria>Participant must male female 18 75 year age , inclusive Participant must give write informed consent initiation studyrelated procedure Participant schedule undergo elective colonoscopy Body Mass Index ( BMI ) 18.0 29.0 kilogram per meter square ( kg/m^2 ) American Society Anesthesiology ( ASA ) class I II Modified Mallampati score I II If female childbearing potential , participant must negative pregnancy test screen breastfeed If participant sexually active male sexually active female childbearing potential , must agree use medically accept form contraception time consent completion followup study visit Any ASA physical status III bad , history one following : history presence significant cardiovascular disease , include atrial fibrillation cardiovascular disease risk factor , hyperlipidemia , coronary artery disease , know genetic pre disposition cardiac arrhythmia ( include long QT syndrome , &gt; 450 millisecond [ msec ] ) ; history neurological seizure disorder psychiatric disease ; history presence significant pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic dermatologic disease ; history illness , opinion investigator , might confound result study pose additional risk participant participation study . History recent illness ( , upper respiratory infection ) satisfy ASA III great requirement opinion investigator , may pose additional risk participant participation study . Participants history essential hypertension well control medication accept . Participants diagnosed hypertension least 6 month and/or stable therapy least 4 week prior study . Surgery within past 90 day prior dose judge investigator clinically relevant . History febrile illness within 5 day prior dose . Participants airway management judge potentially difficult ; thyromental distance â‰¤ 4 centimeter ( cm ) Mallampati score 3 4 per discretion anesthesiologist base history physical exam . History presence alcoholism , drug abuse , illicit drug use within past 2 year . Hypersensitivity idiosyncratic reaction component ABP700 ( sulfobutyletherbetacyclodextrin , citrate buffer , sodium hydroxide ) , remifentanil midazolam . Participant investigator his/her deputy , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct study . Participation another interventional clinical trial within 90 day prior dose . The 90day window derive date last study procedure ( last blood collection dose ) previous study Day 1 current study . Participants , reason , deem investigator inappropriate study , include participant unable communicate cooperate investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Adult participant</keyword>
	<keyword>Sedation</keyword>
	<keyword>elective</keyword>
</DOC>